
Golden Throat Holdings Group Company Limited
6896.HKHKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$2.245
−HK$0.01 · -0.44%
6896.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteGolden Throat Holdings Group Company Limited operates as an investment holding entity primarily engaged in the production and distribution of pharmaceutical goods, health-focused foods, and various other products within the People's Republic of China. Among its offerings are the widely recognized Golden Throat lozenges, an over-the-counter remedy designed to alleviate discomfort from sore and dry throats, as well as hoarseness often stemming from acute pharyngitis. The company further expands its Golden Throat lozenge line with products like Dule lozenges and their sugar-free counterparts, available in diverse flavors including orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn. Additionally, Golden Throat manufactures the Yinxingye tablet, formulated to enhance blood circulation, disperse blood stasis, and clear energy pathways. Its product portfolio also encompasses herbal vegetable beverages, crafted to provide vocal comfort and soothe irritated throats. Beyond its domestic market, the company extends its reach globally, exporting its range of products to countries and regions such as the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and across Africa. Established in 1956, Golden Throat Holdings Group Company Limited maintains its corporate headquarters in Liuzhou, within the People's Republic of China.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Yong Zeng
- Listed since
- Jul 15, 2015
- Employees
- 840
Market position
52-week range
Current HK$2.245
- Open
- HK$2.245
- Previous close
- HK$2.255
- Volume
- 0
- 0× average
- Average volume
- 415.76K
- Average daily volume
- Market cap
- 1.66B HKD
- Beta
- -0.16
- Market reference 1
- 50-day average
- HK$3.1157
- -27.95% below average
- 200-day average
- HK$3.295
- -31.87% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.55B CNY
- P/E (TTM)
- 5.83×
- P/B (TTM)
- 1.03×
- P/S (TTM)
- 1.51×
- EV / EBITDA
- 4.6×
- Earnings yield
- 12.40%
- Free cash flow yield
- 3.85%
- Dividend yield
- 15.14%
Profitability & efficiency
- Gross margin
- 76.01%
- Operating margin
- 32.10%
- Net margin
- 26.63%
- Return on equity
- 18.24%
- Return on assets
- 10.97%
- Return on invested capital
- 11.65%
Financial health
- Debt / equity
- 0.42×
- Current ratio
- 2.17×
- Altman Z-score
- 3.94
- Piotroski F-score
- 7 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 943.26M CNY | 1.19B CNY | 961.38M CNY | 992.01M CNY | 820.54M CNY |
| Cost of goods sold | 226.25M CNY | 290.82M CNY | 263.66M CNY | 271.09M CNY | 242.81M CNY |
| Gross profit | 717.01M CNY | 894.18M CNY | 697.72M CNY | 720.92M CNY | 577.74M CNY |
| Research and development | 3.93M CNY | 32.42M CNY | 17.07M CNY | 6.42M CNY | 22.29M CNY |
| Selling, general, and administrative | 410.3M CNY | 473.04M CNY | 360.98M CNY | 357.6M CNY | 364.79M CNY |
| Operating expenses | 414.22M CNY | 505.46M CNY | 378.05M CNY | 364.02M CNY | 387.07M CNY |
| Interest income | 22.65M CNY | 25.25M CNY | 24.13M CNY | 16.55M CNY | 15.35M CNY |
| Interest expense | 14.38M CNY | 15.36M CNY | 10.7M CNY | 10.29M CNY | 7.98M CNY |
| Depreciation and amortization | 30.34M CNY | 36.43M CNY | 39.03M CNY | 38.64M CNY | 36.98M CNY |
| Operating income | 302.79M CNY | 388.73M CNY | 349.49M CNY | 356.9M CNY | 190.66M CNY |
| Net income | 251.2M CNY | 318.63M CNY | 250.16M CNY | 281.22M CNY | 187.64M CNY |
Company facts updated Aug 25, 2026.
Earnings
- Latest fiscal-year EPS
- 0.34
- FY2025 · -20.93% year over year
- Latest fiscal-year revenue
- 943.26M CNY
- FY2025 · -20.40% year over year
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
6896.HK peers
ETFs holding 6896.HK
Funds reporting this stock among their holdings, ordered by reported position size.
Dimensional - Emerging Markets Core Equity 2 ETFDFEM- Market value
- 111.93K
- Weight
- 0.00%
- AUM
- 9.4B USD
- Expense ratio
- 0.39%
- Price / 1D
- $40.135+1.53%
Dimensional World ex U.S. Core Equity 2 ETFDFAX- Market value
- 49.78K
- Weight
- 0.00%
- AUM
- 12.56B USD
- Expense ratio
- 0.28%
- Price / 1D
- $38.32+0.95%
Dimensional Emerging Markets Sustainability Core 1 ETFDFSE- Market value
- 6.91K
- Weight
- 0.00%
- AUM
- 631.84M USD
- Expense ratio
- 0.44%
- Price / 1D
- $48.895+1.82%
Continue in GoAI
Research 6896.HKresearch.disclaimer





